Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Current Hematologic Malignancy Reports|January 23, 2019
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?Myo Htut
Current Opinion in Oncology|July 17, 2025
Chimeric antigen receptor T-cell therapy for multiple myelomaLawrence Liu, Myo Htut
Plos One|March 17, 2022
Development of near real-time wireless image sequence streaming cloud using Apache Kafka for road traffic monitoring applicationAung Myo Htut, Chaodit Aswakul
Frontiers in Immunology|October 7, 2024
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimenRaya Aliakbar, Olga Manouvakhova, Cindy Wong, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRISPR Knockdown of CHIP Genes in Macrophages Drives Increased Production of Inflammatory Cytokines in CAR-T Cell TherapyChunyan Zhang, Scott R Goldsmith, Myo Htut, et al.
British Journal of Haematology|November 16, 2012
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up studyFiroozeh Sahebi, Yan Shen, Sandra H Thomas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2012
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myelomaAmrita Y Krishnan, Matthew Mei, Can-Lan Sun, et al.
American Journal of Clinical Oncology|March 14, 2024
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple MyelomaColton Ladbury, James Sanchez, Arnab Chowdhury, et al.
F1000Research|December 19, 2015
Audit of antenatal screening for syphilis and HIV in migrant and refugee women on the Thai-Myanmar border: a descriptive studyRose McGready, Joy Kang, Isabella Watts, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Pageof 5